Cagrilintide, also called AM833, is a long-acting amylin analogue studied for weight management, often with semaglutide as CagriSema 1, 5. PubMed-indexed evidence includes multiple human randomized trials in adults with overweight or obesity and type 2 diabetes 1, 2, 4, 5. Cagrilintide is not FDA-approved for weight management or type 2 diabetes; it is investigational. It is not a do-it-yourself peptide; patients should discuss evidence, risks, and legitimate clinical pathways with a licensed clinician.
Wondering if GLP-1 is right for you? Take the 3-min clinical quiz.
See if you qualify →What it is
Cagrilintide is a long-acting amylin analogue, also described as an amylin receptor agonist, that has been studied in human randomized trials for weight management in adults with overweight or obesity 5. In the research literature, it also appears as AM833 and, when studied with semaglutide, as CagriSema 1, 3.
Amylin is a hormone signal linked to appetite and satiety. Cagrilintide research sits near incretin therapy because many trials study it with semaglutide, the active ingredient in Wegovy and Ozempic; Chia offers compounded semaglutide via 503A pharmacy as an injection, with microdosing plans available when clinically appropriate.
Cagrilintide is different from tirzepatide, the active ingredient associated with Mounjaro and Zepbound. Chia offers compounded tirzepatide via 503A pharmacy as tablets and injection, with microdosing plans available after a licensed-provider review. For more background on peptide-based weight medications, see our guide to whether tirzepatide is a peptide.
Names: cagrilintide, AM833, and CagriSema
- Cagrilintide: the main research name used in the published trials.
- AM833: an earlier research identifier used for the same compound in some discussions.
- CagriSema: cagrilintide studied together with semaglutide in randomized trials 1, 2.
- Semaglutide: a GLP-1 receptor agonist studied alone and with cagrilintide in the CagriSema program 3, 4.
Mechanism of action
Cagrilintide’s mechanism is based on amylin signaling, which is tied to appetite regulation and satiety. Human trials have tested the clinical effects of once-weekly cagrilintide for weight management, but receptor-level details in people should be read as a proposed mechanism unless directly measured in the trial being discussed 5.
Amylin signaling, appetite, and satiety
In plain language, amylin-type signaling helps the brain and gut coordinate fullness. Cagrilintide is designed to act longer than natural amylin, and randomized studies have examined whether that signal can support weight-management endpoints in adults with overweight or obesity 5.
Why cagrilintide is studied with semaglutide
Semaglutide is a GLP-1 receptor agonist, while cagrilintide is an amylin analogue. The reason researchers study them together is that they act through different appetite and metabolic signaling pathways, and several randomized trials have evaluated co-administered cagrilintide and semaglutide in adults with overweight, obesity, or type 2 diabetes 1, 2, 4.
Evidence
Evidence grade for cagrilintide: A. A — two or more human randomised controlled trials. B — one human randomised trial, or two or more human clinical trials. C — human research exists, none of it randomised. D — animal or in-vitro research only; no human studies indexed. E — no trial evidence indexed in PubMed. The grade describes the quantity and design of published evidence, not whether the substance works, and not whether it is safe.
The cagrilintide evidence base includes human randomized trials in adults with overweight or obesity, and in adults with type 2 diabetes 1, 2, 5. That is stronger than animal-only or lab-only evidence, but it still needs careful reading because trial populations, endpoints, comparators, and adverse-event monitoring may not match an individual patient.
How to read the evidence grade
A grade A score means the published literature includes at least two human randomized controlled trials. It does not mean cagrilintide is right for a given person, does not remove safety concerns, and does not turn a study protocol into a home dosing plan.
What randomized trials can and cannot prove
Randomized trials can compare outcomes between assigned study groups under close monitoring. For cagrilintide, published randomized studies include once-weekly cagrilintide for weight management, cagrilintide with semaglutide in type 2 diabetes, and CagriSema trials in adults with overweight or obesity 3, 4, 5.
Randomized trials cannot tell a reader whether they personally should use a medication. They also cannot prove safety in every group, especially when a person has complex diabetes therapy, insulin use, gastrointestinal disease, pregnancy considerations, or multiple interacting medicines.
| Comparison | What the evidence in this article supports | What it does not prove |
|---|---|---|
| Cagrilintide alone | Once-weekly cagrilintide was studied in a randomized, double-blind, placebo-controlled and active-controlled phase 2 dose-finding trial for weight management 5. | It does not provide a self-directed dosing plan or prove suitability for every patient. |
| Cagrilintide + semaglutide as CagriSema | Co-administered cagrilintide and semaglutide were studied in multiple randomized trials in adults with overweight, obesity, or type 2 diabetes 1, 2, 4. | It does not mean the combination is interchangeable with any compounded product or appropriate without clinician review. |
| Cagrilintide vs tirzepatide | The retrieved cagrilintide publications here do not provide a direct published tirzepatide comparison that we can cite. | It does not support claims that one is better for a specific person. |
If you are comparing emerging obesity medicines, our separate cagrilintide peptide guide, retatrutide overview, and guide to buying tirzepatide online safely explain related access and safety questions.
What studies exist
| Year | Design | Study | Journal | Record |
|---|---|---|---|---|
| 2025 | Randomised controlled trial | Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes | The New England journal of medicine | PMID 40544432 |
| 2025 | Randomised controlled trial | Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity | The New England journal of medicine | PMID 40544433 |
| 2026 | Randomised controlled trial | Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study | The lancet. Diabetes & endocrinology | PMID 42251859 |
| 2021 | Randomised controlled trial | Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-findin | Lancet (London, England) | PMID 34798060 |
| 2023 | Randomised controlled trial | Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-contr | Lancet (London, England) | PMID 37364590 |
| 2021 | Randomised controlled trial | Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a random | Lancet (London, England) | PMID 33894838 |
| 2025 | Randomised controlled trial | Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept | Molecular metabolism | PMID 41109426 |
| 2026 | Randomised controlled trial | Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity with or without type 2 diabetes in Japan and Taiwa | The lancet. Diabetes & endocrinology | PMID 42009015 |
| 2026 | Randomised controlled trial | Efficacy and safety of zalfermin co-administered with semaglutide in participants with fibrosis and cirrhosis due to metabolic dysfunction-associated steatohepatitis: a phase 2, do | The lancet. Gastroenterology & hepatology | PMID 42456707 |
| 2026 | Randomised controlled trial | Efficacy and safety of once-weekly cagrilintide-semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, dou | The lancet. Diabetes & endocrinology | PMID 42251860 |
| 2026 | Randomised controlled trial | CagriSema Reduces Blood Pressure in Adults With Overweight or Obesity: REDEFINE 1 | Hypertension (Dallas, Tex. : 1979) | PMID 41328546 |
| 1987 | Randomised controlled trial | Single- and multiple-dose pharmacokinetics of fleroxacin, a trifluorinated quinolone, in humans | Antimicrobial agents and chemotherapy | PMID 3125788 |
| Registration | Phase | Status | Enrolment | Title |
|---|---|---|---|---|
| NCT07011667 | PHASE3 | ACTIVE_NOT_RECRUITING | 609 | A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term |
| NCT06267092 | PHASE1 | COMPLETED | 164 | A Study of How CagriSema Works on Appetite in People With Excess Body Weight |
| NCT06719011 | PHASE1 | COMPLETED | 178 | A Study on How NNC0174-1213 Works in People With Overweight or Obesity. |
| NCT06409130 | PHASE2 | COMPLETED | 270 | Effects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease |
| NCT06388187 | PHASE3 | COMPLETED | 300 | A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose Weight |
| NCT07357766 | PHASE3 | WITHDRAWN | — | A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body Weight |
| NCT06534411 | PHASE3 | COMPLETED | 1023 | A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both |
| NCT04940078 | PHASE1 | COMPLETED | 40 | A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Combined Versus Separate Injections in People With Overweight or Obesity |
This table is retrieved from PubMed and ClinicalTrials.gov rather than assembled by hand, so it shows what is indexed — including the absences. Last retrieved 2026-09-09.
Reported dosing ranges
Reported dosing below means doses studied in published or registered trial protocols. It is not a dosing recommendation, not a titration schedule, and not a plan to copy.
| Source | Population studied | Studied dosing information stated in the source | How to read it |
|---|---|---|---|
| Frias et al., Lancet, 2023 | Adults with type 2 diabetes | Co-administered once-weekly cagrilintide 2.4 mg with once-weekly semaglutide 2.4 mg 4. | A phase 2 research protocol, not patient instructions. |
| Enebo et al., Lancet, 2021 | Weight-management study participants | Multiple doses of cagrilintide were administered with semaglutide 2.4 mg in a randomized phase 1b safety, tolerability, pharmacokinetic, and pharmacodynamic study 3. | The PubMed record supports the semaglutide 2.4 mg detail and the multiple-dose design, not a reader dosing plan. |
| Lau et al., Lancet, 2021 | People with overweight or obesity | Once-weekly cagrilintide was studied in a multicenter randomized dose-finding phase 2 trial 5. | Dose-finding means researchers compared assigned trial doses under supervision. |
| REDEFINE 5, Lancet Diabetes & Endocrinology, 2026 | Adults with overweight or obesity, with or without type 2 diabetes, in Japan and Taiwan | Co-administered cagrilintide and semaglutide were compared with semaglutide alone in a randomized phase 3a trial 6. | This supports the trial design and comparison, not home use. |
| REIMAGINE 1 and REIMAGINE 2, Lancet Diabetes & Endocrinology, 2026 | Adults with type 2 diabetes | Once-weekly cagrilintide-semaglutide was studied in randomized phase 3 diabetes trials 8, 9. | Diabetes trial protocols need clinician interpretation, especially when other glucose-lowering medicines are involved. |
Why research doses should not be copied at home
Trial doses are chosen for a study question, not for an anonymous reader. In trials, participants are screened, assigned, monitored, and followed for adverse events; outside that setting, risks can change with other medicines, medical history, pregnancy status, kidney or liver disease, and diabetes therapy.
Legal status
Our regulatory log holds no confirmed federal action for Cagrilintide. That means we have not found one with a primary source — not that none exists.
This section is generated from a dated log of federal actions rather than written by hand, and it is re-checked daily against the Federal Register and FDA sources. Last checked 2026-09-09. See the full legal-status tracker for every compound we follow.
Safety
Safety data for cagrilintide come from controlled research settings, including trials designed to measure safety, tolerability, pharmacokinetics, and pharmacodynamics when cagrilintide was administered with semaglutide 2.4 mg 3. Safety in a trial is not the same as safety for every person.
Gastrointestinal tolerability and dose escalation questions
The key safety theme for cagrilintide and CagriSema research is tolerability, especially because appetite- and gut-signaling medicines can overlap in gastrointestinal effects. Published CagriSema trials explicitly studied efficacy and safety in adults with overweight, obesity, or type 2 diabetes 1, 2, 4, 6.
This is why a clinician review matters. Nausea, vomiting, diarrhea, constipation, dehydration risk, and nutrition changes are the kinds of practical issues a clinician should screen for and monitor when discussing therapies that affect appetite and gut signaling.
Safety limits in people with type 2 diabetes or insulin use
Several cagrilintide-semaglutide trials enrolled adults with type 2 diabetes, including phase 3 studies in adults inadequately controlled on diet and exercise and trials comparing CagriSema with semaglutide or cagrilintide 8, 9. Diabetes studies do not remove the need for careful medication review, because glucose-lowering treatment plans can be complex.
A separate phase 3 study evaluated cagrilintide-semaglutide as an add-on to basal insulin in adults with type 2 diabetes 10. Any therapy studied alongside insulin raises practical questions about hypoglycemia risk, glucose monitoring, and whether diabetes medicines need adjustment by the treating clinician.
Risks of unregulated supply
Products sold as “research use only” are not legitimate clinical care. They may create risks around sterility, identity, strength, impurities, storage, and lack of medical oversight. A licensed clinician and a state-licensed pharmacy are different from a peptide marketplace, group buy, or vendor selling material not made for patient use.
Interactions
Interaction questions for cagrilintide focus on overlap with medicines that affect appetite, gut motility, weight, or blood glucose. The retrieved evidence includes trials with semaglutide and trials in type 2 diabetes populations, but it does not give a complete interaction map for every drug, supplement, or medical condition 3, 4, 8, 9.
Overlap with GLP-1 medications
Cagrilintide has been studied with semaglutide, a GLP-1 receptor agonist, in multiple randomized trials 1, 2, 4. That does not mean it should be layered onto a GLP-1 medication without medical review; overlapping gastrointestinal effects and appetite suppression need clinician oversight.
Diabetes medicines, insulin, and hypoglycemia questions
For people using insulin, sulfonylureas, or other glucose-lowering medicines, the main question is not just weight. It is glucose safety. Cagrilintide-semaglutide has been studied in adults with type 2 diabetes, including a basal-insulin add-on trial, so hypoglycemia risk and monitoring should be part of any clinician discussion 8, 9, 10.
No complete supplement-interaction program is established in the retrieved evidence. That is not reassurance; it means patients should bring a full medication and supplement list to a licensed clinician.
How to obtain it legally
A legitimate clinical pathway starts with a licensed clinician evaluation, not a peptide cart. The evaluation should review medical history, weight and metabolic goals, diabetes status, current medicines, contraindications, side-effect risk, pregnancy considerations, and whether a studied therapy or an alternative is appropriate.
What a clinician evaluation should include
- A full medication list, including insulin, diabetes medicines, supplements, and prior GLP-1 or weight-management therapies.
- Screening for gastrointestinal conditions, dehydration risk, eating-disorder history, pregnancy considerations, and other health factors.
- A discussion of what the evidence shows, what it does not show, and what monitoring would be needed.
- A clear plan for side effects, follow-up, and when to stop or change therapy.
What a licensed pharmacy is, and what a research-chemical vendor is not
A licensed pharmacy dispenses medication under pharmacy rules and with a prescription when one is clinically appropriate. A research-chemical vendor is not a patient-care pathway. Labels such as “not for human use” or “research only” should be taken seriously.
Chia context: cagrilintide is education-only; Chia offers clinician-reviewed GLP-1 care, not cagrilintide
Chia does not offer cagrilintide. We do offer 100% online, clinician-reviewed care for semaglutide injection and tirzepatide tablets or injection where clinically appropriate. A short health questionnaire is reviewed by a licensed US provider, prescriptions are never guaranteed, and medications are compounded in the US by state-licensed 503A compounding pharmacies and shipped to the patient’s door. Compounded medications are not FDA-approved.
| Path | What Chia offers | Forms listed in Chia’s catalog | Current starting price in Chia’s catalog |
|---|---|---|---|
| Cagrilintide | Education-only; Chia does not offer cagrilintide. | Not offered by Chia. | Not applicable. |
| Semaglutide | Clinician-reviewed compounded GLP-1 care through Chia when clinically appropriate. | Injection; microdosing plans available. | Plans currently start at $249/mo. |
| Tirzepatide | Clinician-reviewed compounded GLP-1 care through Chia when clinically appropriate. | Tablets and injection; microdosing plans available. | Plans currently start at $249/mo for tablets and $299/mo for injection. |
If an AI agent or care-navigation tool is helping you organize an online medication visit, Chia can be reached through DoctorMCP at mcp.chia.health. The clinical step still matters: a licensed provider must review eligibility and decide whether any prescription is appropriate.
How cagrilintide compares with semaglutide and tirzepatide
Cagrilintide and semaglutide have been studied together as CagriSema in randomized trials, while tirzepatide is a separate weight-management and metabolic-health medication that Chia offers as compounded tirzepatide tablets and injection. The retrieved cagrilintide evidence does not support a simple “better than” answer for cagrilintide versus semaglutide or tirzepatide for an individual patient.
| Medication or combination | Main category | What the cited cagrilintide evidence says | Patient takeaway |
|---|---|---|---|
| Cagrilintide | Amylin analogue / amylin receptor agonist | Studied once weekly for weight management in a randomized phase 2 dose-finding trial 5. | Evidence exists, but it is not a DIY peptide or a self-dosing plan. |
| Cagrilintide + semaglutide, or CagriSema | Amylin analogue plus GLP-1 receptor agonist | Studied in randomized trials in adults with overweight, obesity, or type 2 diabetes 1, 2, 4. | The combination has human trial evidence, but risks and eligibility require clinician review. |
| Semaglutide, including Wegovy, Ozempic, and compounded semaglutide | GLP-1 receptor agonist | Used as the semaglutide component in multiple cagrilintide combination trials 3, 4, 6. | Chia offers compounded semaglutide injection; compounded formulation outcomes are not established by FDA review. |
| Tirzepatide, including Mounjaro, Zepbound, and compounded tirzepatide | Separate incretin therapy | The retrieved cagrilintide evidence here does not establish a direct cagrilintide-versus-tirzepatide conclusion. | Chia offers compounded tirzepatide tablets and injection; choice of therapy should be clinician-guided. |
Cagrilintide, also called AM833, is a long-acting amylin analogue studied for appetite regulation, satiety, weight management, and type 2 diabetes trial endpoints.
CagriSema is the name used for cagrilintide studied together with semaglutide. Semaglutide is a GLP-1 receptor agonist known by brand names such as Wegovy and Ozempic.
There is no one-size-fits-all answer. Published trials have studied cagrilintide with semaglutide and compared certain study groups, but that does not prove which option is best for a specific person.
Cagrilintide is an amylin analogue. Tirzepatide is a separate incretin therapy associated with the brand names Mounjaro and Zepbound. They are not the same medication and should not be compared as if they were interchangeable.
Cagrilintide is designed to act on amylin signaling, which is linked to appetite and fullness. Human trials have studied it for weight-management and type 2 diabetes-related outcomes.
Some trials studied once-weekly cagrilintide, and one cited phase 2 trial studied cagrilintide 2.4 mg with semaglutide 2.4 mg. These are research protocol details, not instructions for use.
That decision requires a licensed clinician. People with complex diabetes therapy, insulin use, significant gastrointestinal issues, pregnancy considerations, or multiple medications need careful review before considering appetite- or glucose-affecting therapies.
No. Chia does not offer cagrilintide. Chia does offer clinician-reviewed compounded semaglutide injection and compounded tirzepatide tablets or injection through licensed US providers and state-licensed 503A pharmacies; compounded drugs are not FDA-approved.
References
- 1.PMID 40544433 [randomised controlled trial] Garvey WT, Blüher M, Osorto Contreras CK, et al. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. The New England journal of medicine. 2025.
- 2.PMID 40544432 [randomised controlled trial] Davies MJ, Bajaj HS, Broholm C, et al. Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes. The New England journal of medicine. 2025.
- 3.PMID 33894838 [randomised controlled trial] Enebo LB, Berthelsen KK, Kankam M, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial. Lancet (London, England). 2021.
- 4.PMID 37364590 [randomised controlled trial] Frias JP, Deenadayalan S, Erichsen L, et al. Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial. Lancet (London, England). 2023.
- 5.PMID 34798060 [randomised controlled trial] Lau DCW, Erichsen L, Francisco AM, et al. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. Lancet (London, England). 2021.
- 6.PMID 42009015 [randomised controlled trial] Yamauchi T, Becker NP, Hagemann CA, et al. Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity with or without type 2 diabetes in Japan and Taiwan (REDEFINE 5): a multicentre, randomised, active-controlled, phase 3a trial. The lancet. Diabetes & endocrinology. 2026.
- 7.PMID 41328546 [randomised controlled trial] Verma S, Böttcher M, Brown P, et al. CagriSema Reduces Blood Pressure in Adults With Overweight or Obesity: REDEFINE 1. Hypertension (Dallas, Tex. : 1979). 2026.
- 8.PMID 42251859 [randomised controlled trial] Buse JB, Bajaj HS, Dalskov SM, et al. Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study. The lancet. Diabetes & endocrinology. 2026.
- 9.PMID 42251860 [randomised controlled trial] Aroda VR, Buzzetti R, Dalskov SM, et al. Efficacy and safety of once-weekly cagrilintide-semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study. The lancet. Diabetes & endocrinology. 2026.
- 10.PMID 42251856 [randomised controlled trial] Rosenstock J, Billings LK, Gajria R, et al. Cagrilintide-semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study. Lancet (London, England). 2026.
- 11.PubMed search record for ("Cagrilintide" OR "AM833") used to generate indexed-record and filter counts. Last retrieved 2026-09-09.
About this article
Chia Health Editorial Team — Evidence-reviewed health education
This article is for educational purposes only and is not a substitute for individualized medical advice. Talk to a licensed clinician before starting, stopping, or changing any prescription.
AI tools may assist with research and drafting. Chia's editorial team reviews source use, clarity, treatment information, and safety framing before publication. A clinician is named only after explicit sign-off. Read our editorial standards.
Get a personalized plan
See if GLP-1 is right for your body.
Our 3-minute clinical quiz is reviewed by a US-licensed clinician. Treatment delivered to your door.
